Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SURESH G NAIR

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1669423711
CMS profile
166428
Location
ALLENTOWN, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$295.85

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $252.60 3
Education $43.25 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Exelixis Inc. $175.00 1
HISTOSONICS, INC. $43.84 1
AstraZeneca Pharmaceuticals LP $43.25 1
Immunocore Limited $33.76 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SURESH G NAIR

NPI 1669423711 · CMS profile ID 166428

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ALLENTOWN, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669423711?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SURESH G NAIR, NPI 1669423711, CMS profile ID 166428. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669423711?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SURESH G NAIR, NPI 1669423711, CMS profile ID 166428. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669423711?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SURESH G NAIR, NPI 1669423711, CMS profile ID 166428, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1669423711?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $295.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $43.2511/25/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1206360854 CMS
Immunocore Limited $33.7609/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235826293 CMS
Exelixis Inc. $175.0005/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218805881 CMS
HISTOSONICS, INC. $43.8401/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233991426 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $125.76 9
PY2020 $69.07 4
PY2021 $61.31 4
PY2022 $80.04 1
PY2023 $78.24 1
PY2024 $149.49 2
PY2025 $295.85 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $194,965.34 40
PY2024 Principal investigator $148,310.84 44
PY2023 Principal investigator $382,804.46 29
PY2022 Principal investigator $135,383.95 27
PY2021 Principal investigator $617,414.43 31
PY2020 Principal investigator $541,006.34 33
PY2019 Principal investigator $398,239.66 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $5,967.25 12/31/2024 Covered Recipient Teaching Hospital
Lehigh Valley
A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma mRCC KEYNOTE-426 No dispute reported 06/30/2026 1136410995
Principal investigator 1 Merck Sharp & Dohme LLC $18,810.41 12/31/2024 Covered Recipient Teaching Hospital
Lehigh Valley
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy No dispute reported 06/30/2026 1136424741
Principal investigator 1 Merck Sharp & Dohme LLC $5,327.76 12/02/2024 Covered Recipient Teaching Hospital
Lehigh Valley
A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma mRCC KEYNOTE-426 No dispute reported 06/30/2026 1136410991
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,086.94 10/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505111
Principal investigator 1 Aveo Pharmaceuticals, Inc. $143.00 10/16/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505057
Principal investigator 1 Aveo Pharmaceuticals, Inc. $143.00 10/16/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505062
Principal investigator 1 Aveo Pharmaceuticals, Inc. $429.66 10/16/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505068
Principal investigator 1 Aveo Pharmaceuticals, Inc. $110.65 10/16/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505075
Principal investigator 1 Aveo Pharmaceuticals, Inc. $110.65 10/16/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505083
Principal investigator 1 Aveo Pharmaceuticals, Inc. $110.65 10/16/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505089
Principal investigator 1 Aveo Pharmaceuticals, Inc. $429.66 10/16/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505095
Principal investigator 1 Aveo Pharmaceuticals, Inc. $283.50 10/16/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505103
Principal investigator 1 Merck Sharp & Dohme LLC $1,500.00 09/16/2024 Covered Recipient Teaching Hospital
Lehigh Valley
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy No dispute reported 06/30/2026 1136424737
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,808.59 08/29/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505052
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,288.98 07/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505002
Principal investigator 1 Aveo Pharmaceuticals, Inc. $429.00 07/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505010
Principal investigator 1 Aveo Pharmaceuticals, Inc. $3,319.39 06/28/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504994
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $11,675.00 05/24/2024 Covered Recipient Teaching Hospital
Lehigh Valley
MAST Phase III 1L GBM Methylated (nivo mono chemo RT) - A Randomized Phase 3 Single Blind Study of Temozolomide plus Radiation Therapy co mbined with Nivo lumab or Placebo in Newly Diagnosed Adult Subjects with MGMT -Methylated (tumor O6-methylguanine DN No dispute reported 06/30/2026 1123473209
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,500.00 05/09/2024 Covered Recipient Teaching Hospital
Lehigh Valley
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies No dispute reported 06/30/2026 1123473211
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,700.00 05/03/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
Phase III 1L Metastatic RCC Nivo/Ipi/Cabo No dispute reported 06/30/2026 1123478351
Principal investigator 1 Aveo Pharmaceuticals, Inc. $715.00 03/04/2024 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504920
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,148.30 03/04/2024 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504925
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,330.69 02/28/2024 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504837
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,330.69 02/28/2024 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504841
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,330.69 02/28/2024 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504847
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,330.69 02/28/2024 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504854
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,330.69 02/28/2024 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504857
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,330.69 02/28/2024 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504864
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,330.69 02/28/2024 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504870
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,330.69 02/28/2024 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504877
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,330.69 02/28/2024 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504884
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,330.69 02/28/2024 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504890
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,296.97 02/28/2024 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504894
Principal investigator 1 Aveo Pharmaceuticals, Inc. $3,282.27 02/28/2024 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504901
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,887.87 02/28/2024 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504907
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,330.69 02/28/2024 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143504914
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,196.00 02/16/2024 Covered Recipient Teaching Hospital
Lehigh Valley
PhIII Stage 3/4 Resectable Mel Adj Rela+Nivo vs Nivo - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab andNivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma [ No dispute reported 06/30/2026 1123473239
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,125.75 02/08/2024 Covered Recipient Teaching Hospital
Lehigh Valley
Pan-Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab No dispute reported 06/30/2026 1155196425
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,689.00 02/06/2024 Covered Recipient Teaching Hospital
Lehigh Valley
Phase III NSCLC 1L (combo) - An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Na ve Stage IV or Recurrent No dispute reported 06/30/2026 1123473227
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,650.00 01/31/2024 Covered Recipient Teaching Hospital
Lehigh Valley
Phase IIB Hodgkins Lymphoma No dispute reported 06/30/2026 1123473219
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,456.00 01/16/2024 Covered Recipient Teaching Hospital
Lehigh Valley
Phase III Adjuvant Melanoma Monotherapy No dispute reported 06/30/2026 1123473223
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,250.00 01/08/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
Phase III Nivo+Ipi vs Placebo in Adjuvant RCC (Part B FA) - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Par No dispute reported 06/30/2026 1123478361
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,152.00 01/04/2024 Covered Recipient Teaching Hospital
Lehigh Valley
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) No dispute reported 06/30/2026 1123473229
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,650.00 01/03/2024 Covered Recipient Teaching Hospital
Lehigh Valley
Phase III MEL 1L, PD-1 vs Ipi vs. PD-1+Ipi - A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 1123473225